{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:33:01Z","timestamp":1777883581484,"version":"3.51.4"},"reference-count":86,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Franco-American Fulbright Commission"},{"name":"US Fulbright program"},{"DOI":"10.13039\/100020090","name":"Fondation Neurodis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020911","name":"Centre Hospitalier Le Vinatier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Opioid agonist therapies (OAT), including methadone and buprenorphine, are first-line care in national and international guidelines, yet many countries, including the United States, frequently fail to effectively engage and retain people in OAT. How OAT is delivered\u2014including the goals and culture of care\u2014matters to patient engagement, treatment retention, and health outcomes. France has among the highest OAT receipt and lowest opioid-related morbidity and mortality worldwide. This study explored French interprofessional health care clinicians\u2019 approach to OAT, drawing lessons to improve OAT implementation in the United States and elsewhere.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We recruited interprofessional participants (eg, physicians, pharmacists, nurses, administrators) from diverse health care settings (eg, specialty addiction care, hospitals, public health) and regions and conducted in-depth semi-structured qualitative interviews. We conducted a reflexive thematic analysis using an inductive approach at a semantic level, identifying themes that held meaning to study participants and had implications for the United States and other contexts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-one people participated. Participants described patient engagement as the primary goal of OAT, which has potential to draw people to care. They felt imposing or expecting abstinence was harmful and might obligate patients to lie or \u201clead a double life,\u201d resulting in mistrust, missed care opportunities, and \u201closing patients\u201d who disengaged from care. Participants described balancing flexibility and structure. They felt that flexibility promotes OAT access and engagement and that clinicians should contextualize decisions within patients\u2019 risk environments, including those of an illicit drug supply and the black market. Participants described that structure should be offered as support, not punishment or control. Finally, they described that practices prioritizing engagement are sustained by policies and professional norms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our findings challenge OAT practices and policies centered on abstinence and control. They suggest that approaches that prioritize patient engagement and balance flexibility and structure may be central to achieving high rates of OAT across a population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342251324325","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T08:36:32Z","timestamp":1742891792000},"page":"643-653","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cUn attracteur de soins\u201d: Bringing People Into Care. Interdisciplinary Health Care Professionals\u2019 Attitudes Toward Opioid Agonist Therapy in France: a Qualitative Study with Implications for the United States"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-2041","authenticated-orcid":false,"given":"Honora","family":"Englander","sequence":"first","affiliation":[{"name":"Section of Addiction Medicine in General Internal Medicine, Department of Medicine, Oregon Health &amp; Science University, Portland, OR, USA"},{"name":"Service Universitaire d\u2019Addictologie de Lyon, Centre Hospitalier Le Vinatier, Bron, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Rolland","sequence":"additional","affiliation":[{"name":"Service Universitaire d\u2019Addictologie de Lyon, Centre Hospitalier Le Vinatier, Bron, France"},{"name":"Centre de Soins d\u2019Accompagnement et de Pr\u00e9vention en Addictologie, Hospices Civils de Lyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Jauffret-Roustide","sequence":"additional","affiliation":[{"name":"Centre d\u2019\u00e9tude des Mouvements Sociaux (Inserm U1276\/CNRS UMR8044\/EHESS), Paris, France"},{"name":"Institut Universitaire sur les D\u00e9pendances, Montr\u00e9al, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.10.009"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","unstructured":"Degenhardt L Grebely J Stone J et al. Global patterns of opioid use and dependence: harms to populations interventions and future action. Lancet. 2019;394(10208):1560-1579. doi:https:\/\/doi.org\/10.1016\/S0140-6736(19)32229-9","DOI":"10.1016\/S0140-6736(19)32229-9"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/adm.0000000000000633"},{"key":"e_1_3_3_8_2","unstructured":"Bertin Cea. Haute Autorit\u00e9 de sant\u00e9 (HAS): Bon usage des m\u00e9dicaments opio\u00efdes: antalgie pr\u00e9vention et prise encharge du trouble de l\u2019usage et des surdoses. Best Practice Recommendations published online 24 March 2022. Accessed Nov 24 2024. https:\/\/www.has-sante.fr\/jcms\/p_3215131\/fr\/bon-usage-des-medicaments-opioides-antalgie-prevention-et-prise-en-charge-du-trouble-de-l-usage-et-des-surdoses"},{"key":"e_1_3_3_9_2","article-title":"WHO Guidelines Approved by the Guidelines Review Committee","author":"WHO","year":"2009","unstructured":"WHO. WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. 2009.","journal-title":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15087"},{"key":"e_1_3_3_11_2","unstructured":"European Monitoring Centre for Drugs and Drugs Addiction (EMCDDA). Opioid agonist treatment\u2014the current situation in Europe (European Drug Report 2024). 2024. Accessed June 24 2024. https:\/\/www.emcdda.europa.eu\/sites\/default\/files\/pdf\/31793_en.pdf?536679"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103786"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27488"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2018.1546862"},{"key":"e_1_3_3_15_2","unstructured":"Dale-Perera A. Recovery reintegration abstinence harm reduction: the role of different goals within drug treatment in the European context. Report for the European Monitoring Centre for Drugs and Drug Addiction. 2017. Accessed November 21 2024. https:\/\/www.emcdda.europa.eu\/document-library\/recovery-reintegration-abstinence-harm-reduction-role-different-goals-within-drug-treatment-european-context_en"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2021.2010251"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00535-y"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.2021.306665"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104487"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.102614"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550490490440780"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-007-0046-2"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01271.x"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2021.1975872"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209182"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2312906"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/adm.0000000000001388"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2024.00461"},{"key":"e_1_3_3_29_2","unstructured":"OFDT. Traitments de Substitution aux Opioids en France Bilan 2023. Accessed September 24 2024. http:\/\/www.ofdt.fr\/BDD\/publications\/docs\/TabTSO230418.pdf"},{"key":"e_1_3_3_30_2","first-page":"161","article-title":"La r\u00e9duction des risques: enjeux autour d\u2019une mobilisation collective","volume":"8","author":"Jauffret-Roustide M.","year":"2000","unstructured":"Jauffret-Roustide M. La r\u00e9duction des risques: enjeux autour d\u2019une mobilisation collective. Mana Rev Soc Anthropol. 2000;8:161-188.","journal-title":"Mana Rev Soc Anthropol"},{"key":"e_1_3_3_31_2","volume-title":"L\u2019 \u00c9tat et la toxicomanie: histoire d\u2019une singularit\u00e9 fran\u00e7aise","author":"Bergeron H.","year":"1999","unstructured":"Bergeron H. L\u2019 \u00c9tat et la toxicomanie: histoire d\u2019une singularit\u00e9 fran\u00e7aise. Presses universitaires de France; 1999."},{"key":"e_1_3_3_32_2","volume-title":"Rapport de la commission de r\u00e9flexion sur la drogue et la toxicomanie","author":"Henrion R.","year":"1995","unstructured":"Henrion R. Rapport de la commission de r\u00e9flexion sur la drogue et la toxicomanie. Minist\u00e8re des Affaires sociales, de la sant\u00e9, et de la Ville; 1995."},{"key":"e_1_3_3_33_2","volume-title":"Les drogues: approche sociologique, \u00e9conomique et politique","author":"Jauffret-Roustide MD.","year":"2004","unstructured":"Jauffret-Roustide MD. Les drogues: approche sociologique, \u00e9conomique et politique. La Documentation fran\u00e7aise; 2004."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(01)00161-2"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.2022.306763"},{"key":"e_1_3_3_36_2","author":"Spiller T","year":"2023","unstructured":"Spiller T, Ben-Zion Z, Korem N, Harpaz-Rotem I, Duek O. Efficient and accurate transcription in mental health research\u2014a tutorial on using whisper AI for sound file transcription. 2023.","journal-title":"Efficient and accurate transcription in mental health research\u2014a tutorial on using whisper AI for sound file transcription"},{"key":"e_1_3_3_37_2","unstructured":"Dedoose Version 9.0. 17 Cafm Analyzing and Presenting Qualitative and Mixed Method Research Data. SocioCultural Research Consultants LLC; 2021. www.dedoose.com"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1037\/qup0000196"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/acm.0000000000000388"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.31478\/202309b"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/amajethics.2024.562"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4603(96)00042-1"},{"key":"e_1_3_3_44_2","unstructured":"Jauffret-Roustide M. Du point de vue des usagers quels sont les effets les b\u00e9n\u00e9fices et les difficult\u00e9s suscit\u00e9s par les TSO? Alcoologie et Addictologie. 2004; 26(Suppl 4):328S-35S"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/acer.14765"},{"key":"e_1_3_3_46_2","article-title":"Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63","author":"Substance Abuse and Mental Health Services Administration","year":"2021","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Rockville, MD; 2021.","journal-title":"Rockville, MD;"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.208954"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.7326\/l19-0145"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.5617\/jea.6737"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.2020.81.405"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/adm.0000000000001408"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.18487"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bjsw.a011422"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.3109\/10826089909039442"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07939-x"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2019.00056"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104645"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2024.209616"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0376-8716(03)00055-3"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480160092041"},{"key":"e_1_3_3_61_2","volume-title":"Proceedings of a Workshop","author":"Stroud C","year":"2022","unstructured":"Stroud C, Norris SMP, Bain L. Methadone treatment for opioid use disorder: improving access through regulatory and legal change. In: Proceedings of a Workshop. Washington (DC): National Academies Press (US); 2022."},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15190"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209055"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1097\/adm.0000000000000555"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2310171"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2020.1824046"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00676-8"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxad018"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100636"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-018-4801-3"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/adm.0000000000000841"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19914"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1177\/29767342241255480"},{"key":"e_1_3_3_74_2","unstructured":"Haute Autorit\u00e9 de sant\u00e9 (HAS): La pr\u00e9vention des addictions et la r\u00e9duction des risques et des dommages par les centres de soins d\u2019accompagnement et de pr\u00e9vention en addictologie (CSAPA). Published online 27 January 2020. Accessed September 24 2024."},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00251-9"},{"key":"e_1_3_3_76_2","unstructured":"H.R.2617\u2014Consolidated Appropriations Act 2023. 2022."},{"key":"e_1_3_3_77_2","unstructured":"Expansion of Buprenorphine Treatment via Telemedicine Encounter 90 FR 6504 (2025). 2025."},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2021.1986768"},{"key":"e_1_3_3_79_2","unstructured":"S.644\u2014Modernizing Opioid Treatment Access Act (M-OTAA). Accessed March 20 2024. https:\/\/www.congress.gov\/bill\/118th-congress\/senate-bill\/644?q=%7B%22search%22%3A%22S+644%22%7D&s=1&r=14"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.2993"},{"issue":"5","key":"e_1_3_3_81_2","first-page":"327","article-title":"Mutual mistrust in the medical care of drug users: the keys to the \u201cnarc\u201d cabinet","volume":"17","author":"Merrill JO","year":"2002","unstructured":"Merrill JO, Rhodes LA, Deyo RA, Marlatt GA, Bradley KA. Mutual mistrust in the medical care of drug users: the keys to the \u201cnarc\u201d cabinet. J Gen Intern Med. 2002;17(5):327-333.","journal-title":"J Gen Intern Med"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108455"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108146"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-8-17"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401177"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.3436"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.3422"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342251324325","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342251324325","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342251324325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:50:56Z","timestamp":1777600256000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342251324325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/29767342251324325"],"URL":"https:\/\/doi.org\/10.1177\/29767342251324325","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}